Table 3 The details of the side effects of each regimen used in first-line chemotherapy
| Â | Â | Gastrointestinal toxicity | Â | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neutropenia | Anemia | Thrombocytopenia | Nausia/Vomitting | Diarrea | Constipation | Mucositis | FN | ||||||||||||||||||||||
grade | grade | grade | grade | grade | grade | grade | grade | ||||||||||||||||||||||
1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 3 | |
S-1 (n = 13) | 2 | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 2 | 1 | 0 | 2 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
S-1 + cisplatin (n = 19) | 5 | 2 | 2 | 3 | 4 | 2 | 0 | 0 | 4 | 2 | 0 | 1 | 5 | 4 | 2 | 0 | 4 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 2 |
IP (n = 15) | 2 | 1 | 3 | 2 | 1 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
S-1 + oxaliplatin (n = 13) | 4 | 2 | 1 | 0 | 3 | 2 | 1 | 0 | 1 | 4 | 0 | 0 | 4 | 2 | 0 | 0 | 2 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
S-1 + docetaxel (n = 10) | 2 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
Capecitabine + oxaliplatin (n = 5) | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Capecitabine + cisplatin (n = 3) | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Capecitabine + trastuzumab (n = 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
S-1 + cisplatin + docetaxel (n = 2) | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |